A novel approach toward development of a rapid blood test for breast cancer.
Mammography remains the diagnostic test of choice for breast cancer, but 20% of cancers still go undetected. Many serum biomarkers have been reported for breast cancer but none have proven to represent effective diagnostic strategies. ProteinChip mass spectrometry is an innovative technology that se...
| Published in: | Clinical Breast Cancer Vol. 4; no. 3; pp. 203 - 210 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Elsevier B.V.
2003 Aug
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106783691&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106783691 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15268209 G4D jtl: Clinical Breast Cancer issn: 15268209 maglogo: N pubinfo: dt: 2003 Aug vid: 4 iid: 3 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 106783691 106783691 NLM14499014 2003158155 NLM14499014 106783691 ppf: 203 ppct: 7 formats: tig: atl: A novel approach toward development of a rapid blood test for breast cancer. aug: au: Vlahou A Laronga C Wilson L Gregory B Fournier K McGaughey D Perry RR Wright GL Jr. Semmes OJ Vlahou, Antonia Laronga, Christine Wilson, Lori Gregory, Betsy Fournier, Keith McGaughey, Dean Perry, Roger R Wright, George L Jr Semmes, O John affil: Department of Microbiology, and Virginia Prostate Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA sug: subj: Breast Neoplasms Blood Breast Neoplasms Diagnosis Hematologic Tests Methods Hematologic Tests Trends Adult Aged Aged, 80 and Over Algorithms Biological Markers Female Funding Source Middle Age Sensitivity and Specificity Software Time Factors Validation Studies Human Adult: 19-44 years Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years Female ab: Mammography remains the diagnostic test of choice for breast cancer, but 20% of cancers still go undetected. Many serum biomarkers have been reported for breast cancer but none have proven to represent effective diagnostic strategies. ProteinChip mass spectrometry is an innovative technology that searches the proteome for differentially expressed proteins, allowing for the creation of a panel or profile of biomarkers. The objective of this study was to construct unique cancer-associated serum profiles that, combined with a classification algorithm, would enhance the detection of breast cancer Pretreatment serum samples from 134 female patients (45 with cancer, 42 with benign disease, 47 normal) were procured prospectively following institutional review board-approved protocols. Proteins were denatured, applied onto ProteinChip affinity surfaces, and subjected to surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry. The SELDI output was analyzed using Biomarker Pattern Software to develop a classification tree based on group-specific protein profiles. The cross-validation analysis of cancer versus normal revealed sensitivity and specificity rates of 80% and 79%, and for cancer versus benign disease, 78% and 83%, respectively. When 2 different chip surfaces were combined the sensitivity and specificity increased to 90% and 93%, respectively. The sensitivity and specificity of this technique are comparable to those of mammography and, if confirmed in a larger study, this technique could provide the means toward development of a simple blood test to aid in the early detection of breast cancer. The combination of SELDI ProteinChip mass spectrometry and a classification- and regression-tree algorithm has the potential to use serum protein expression profiles for detection and diagnosis of breast cancer. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|